The tweet was deleted by the author.
But we saved everything 🙂.
Amgen highlights the importance of early-stage intervention in managing atherosclerotic cardiovascular disease (ASCVD). For many patients, a cardiovascular event signals the commencement of chronic disease management, which involves ongoing medical costs beyond the initial incident.
Amgen suggests positioning cardiologists and primary care physicians earlier in the treatment process to potentially improve patient outcomes. This approach may help mitigate long-term healthcare expenses related to ASCVD.